Upregulation of MYBL2 independently predicts a poorer prognosis in patients with clear cell renal cell carcinoma

作者：Shanshan Sun, Yang Fu, Jianyang Lin · 发表于：Oncology Letters · 年份：2020 · DOI：10.3892/ol.2020.11408 · 被引用次数：15 · 研究领域：Ferroptosis and cancer prognosis、Genetic factors in colorectal cancer、Renal cell carcinoma treatment

MYB protooncogene‑like 2 (MYBL2) is a transcription factor that is upregulated and significantly associated with various human cancer types. However, the potential role of MYBL2 in clear cell renal cell carcinoma (ccRCC) is yet to be elucidated. Therefore, the expression and biological functions of MYBL2 in ccRCC were assessed in the current study using The Cancer Genome Atlas (TCGA). A Wilcoxon signed‑rank test was performed to compare MYBL2 expression between ccRCC and normal tissues. Moreover, the association between MYBL2 expression and various clinicopathological factors was estimated using both the Wilcoxon signed‑rank test and logistic regression. The differences in prognosis between patients with high‑ and low‑MYBL2 expression were analyzed via the Kaplan‑Meier method and Cox regression analysis. Finally, gene set enrichment analysis (GSEA) was performed to investigate the biofunctions of MYBL2 in ccRCC. It was revealed that MYBL2 was upregulated in ccRCC, and that the MYBL2 high‑expression phenotype was significantly associated with sex, a high histological grade, an advanced clinical stage, tumor stage, lymph node metastasis, distant metastasis and poor overall survival (OS). It was also revealed, via the Cox regression analysis, that the upregulation of MYBL2 expression was able to independently predict a poor prognosis in patients with ccRCC. GSEA indicated that the intestinal immune network for IgA production, primary immunodeficiency, the janus kinase (JAK)‑sign...